Rossi A C, Hsu J P, Faich G A
Br Med J (Clin Res Ed). 1987 Jan 17;294(6565):147-50. doi: 10.1136/bmj.294.6565.147.
Previous reports have suggested that piroxicam may be more ulcerogenic than other non-steroidal anti-inflammatory drugs (NSAIDs) in use. Critics have attributed this putative relation to flawed comparisons of spontaneously reported data. In this study cases of upper gastrointestinal bleeding, perforation, and ulcer reported to the Food and Drug Administration's spontaneous reporting system over 12 years were examined. Reporting rates for eight NSAIDs were compared over identical periods of their marketing life cycles. After adjustments were made for the heterogeneity in the underlying reporting rates the difference in rates between piroxicam and the other drugs was considerably reduced but piroxicam retained its top ranking among the drugs; however, large and clinically important differences in the frequency of cases of upper gastrointestinal bleeding, perforation, and ulcer between piroxicam and the rest of the NSAIDs compared probably do not exist.
先前的报告表明,在使用的非甾体抗炎药(NSAIDs)中,吡罗昔康可能比其他药物更易引发溃疡。批评者将这种假定的关系归因于对自发报告数据的有缺陷比较。在本研究中,对向美国食品药品监督管理局自发报告系统报告的12年期间的上消化道出血、穿孔和溃疡病例进行了检查。比较了8种NSAIDs在其相同的上市生命周期内的报告率。在对基础报告率的异质性进行调整后,吡罗昔康与其他药物之间的率差大幅降低,但吡罗昔康在这些药物中仍排名第一;然而,吡罗昔康与其他NSAIDs相比,在上消化道出血、穿孔和溃疡病例频率上可能不存在大的且具有临床重要性的差异。